Anavex Life Sciences Corp (AVXL)
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing treatments for disorders of the central nervous system and other serious conditions. Its research pipeline includes programs for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental and neurodegenerative disorders, Rett syndrome, pain, and certain cancers. The company’s lead candidate, ANAVEX 2-73 (blarcamesine), is an orally available compound designed to help restore cellular balance through activity at SIGMAR1 and muscarinic receptors. It has been studied in multiple clinical programs, including trials in Alzheimer’s disease, Parkinson’s disease dementia, and Rett syndrome. Anavex also is advancing ANAVEX 3-71, a clinical-stage candidate targeting SIGMAR1 and M1 muscarinic receptors, with preclinical data in Alzheimer’s disease models. Founded in 2004, the company is headquartered in New York, New York.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AVXL
|
$2.94
|
17.3% Upside
|
Fair
|
$20
|
696.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-5.8x
|
1.8x
|
—
|
224.3 M
|
101.3 M
|
0.0%
|
96.9%
|
17.1
|
—
|
85.3%
|
